Most Recent
ASIC has told a judge AMP should face a $17.5 million penalty for deducting $356,000 from customers' superannuation accounts for advice they never received, saying the wealth manager had shown "no real contrition" for its conduct.
A judge has fined superannuation fund promoter MobiSuper and licensee ZIB Financial $250,000 for misleading marketing calls.
The former legal representatives of James Mawhinney have hit back at allegations of incompetence by the embattled Mayfair 101 founder on the last day of his appeal against decisions that saw him banned from soliciting funds or promoting any financial product for 20 years.
A judge has ruled that separate breaches of statutory building warranties do not create individual causes of action, in a win for an owners corporation bringing claims against the builder of an allegedly defective Haymarket apartment building.
UK automotive distributor Inchcape has challenged a judgment that put insurer Chubb on the hook for some but not all of the financial losses stemming from a cyberattack that allegedly caused $4 million in loss.
Cricket Australia says the COVID-19 pandemic was a force majeure event under its broadcast agreement with the Seven Network, which has sued the sporting governing body over alleged breaches of the deal.
Mercedes-Benz will face a penalty in ACCC proceedings alleging the luxury car maker exposed consumers to serious injury or death by failing to comply with obligations under a compulsory recall of potentially deadly Takata airbags.
Westpac and the lead applicant in a class action filed in the wake of AUSTRAC proceedings are still battling it out over discovery of evidence three years into the case. And the applicant claims the bank's discovery protocol fails the new test set by the Full Federal Court earlier this year.
South Korean car makers Hyundai and Kia are facing a class action investigation in Australia over cars containing potentially defective petrol engines, after agreeing to a settlement worth more than $1 billion in related US litigation last year.
Two law firms that filed competing class actions against regenerative medicine company Mesoblast for allegedly misleading shareholders about its Remestemcel-L treatment for COVID-19 complications have agreed to join forces and sidestep a beauty parade.